Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as 0.2% topical corticosteroid solution
SURF-201 · 1 trial · 2 indications
The Investigator used a slit lamp biomicroscope to assess ACCs in the study (surgery) eye. ACC counts were graded as follows: ACC Grade 0 = 0 cells were seen ACC Grade higher than 0 = 1 or more cells were seen
| Arm | Type | Description |
|---|---|---|
| SURF-201 | EXPERIMENTAL | 0.2% topical preservative-free corticosteroid solution (0.2% betamethasone sodium phosphate) |
| Vehicle | PLACEBO_COMPARATOR | Topical preservative-free vehicle (Placebo) |
| Name | Type | Description |
|---|---|---|
| SURF-201 | DRUG | One drop twice daily (BID) in the study eye for 16 days. |
| Placebo | DRUG | One drop twice daily (BID) in the study eye for 16 days. |
Inclusion Criteria: 1. Adult subjects age 18 years or older scheduled for uncomplicated unilateral cataract surgery with posterior chamber intraocular lens (IOL) implantation. 2. Subjects must be able to understand and sign the Informed Consent Form (ICF). 3. Female subjects of childbearing potenti...
SURF-201 is an investigational small molecule eye drop being developed by Harrow, Inc. for post-surgical ocular inflammation. It is a Phase 2 clinical-stage candidate studied in cataract surgery patients in the United States. SURF-201 has not been approved by the FDA and remains in clinical development.
SURF-201 is being studied for post-surgical ocular inflammation following cataract surgery. The Phase 2 trial also enrolled patients with post-surgical ocular pain. It is an investigational therapy and is not approved for any indication.
SURF-201 is being developed by Harrow, Inc., which trades on the Nasdaq under the ticker HROW. Harrow is an ophthalmology-focused pharmaceutical company, and SURF-201 is its small molecule eye drop candidate for post-surgical ocular inflammation.
SURF-201 is in Phase 2 development. One Phase 2 trial has been completed, and no trials are currently active. The program has not been approved by the FDA, so SURF-201 remains an investigational drug in clinical development for post-surgical ocular inflammation.
SURF-201 has been evaluated in one completed Phase 2 trial, NCT04324359, titled a study of the eye drop SURF-201 in cataract surgery subjects. The trial enrolled 91 participants in the United States, was randomized, double-blind, and placebo-controlled, and included adults 18 years and older.
The Phase 2 trial of SURF-201, NCT04324359, enrolled 91 participants. It was a randomized, double-blind, placebo-controlled study conducted in the United States in adults aged 18 years and older undergoing cataract surgery, evaluating post-surgical ocular inflammation and post-surgical ocular pain.